Buruli ulcer

Clinics in Dermatology

Volumn 27, Issue 3, 2009, Pages 291-305

  Portaels, Françoise ^a   Silva, Manuel T ^b   Meyers, Wayne M ^c  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF PORTO   (Portugal)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITROGEN OXIDE; PHENYTOIN; RIFAMPICIN; STREPTOMYCIN;

ARTICLE; ASPIRATION BIOPSY; BACTERIAL IMMUNITY; BACTERIUM CULTURE; BURULI ULCER; CLAY; DISEASE COURSE; DISEASE TRANSMISSION; EXCISION; HISTOPATHOLOGY; HOST PATHOGEN INTERACTION; HUMAN; HYPERTHERMIC THERAPY; MYCOBACTERIUM ULCERANS; NONHUMAN; OSTEOMYELITIS; PATHOGENESIS; PHYSIOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADOLESCENT; AGED; BURULI ULCER; CHILD; FEMALE; HUMANS; MALE;

EID: 64149096136     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2008.09.021     Document Type: Article

References (96)

1. Sizaire V., Nackers F., Comte E., and Portaels F. Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect Dis 6 (2006) 288-296
2. MacCallum P., Tolhurst J.C., Buckle G., and Sissons H.A. A new mycobacterial infection in man. J Pathol Bacteriol 60 (1948) 93-122
3. Janssens P.G., Pattyn S.R., Meyers W.M., and Portaels F. Buruli ulcer: an historical overview with updating to 2005. Bull Séances Acad R Sci Outre-Mer 51 (2005) 165-199
4. Clancey J.K., Dodge O.G., Lunn H.F., and Oduori M.L. Mycobacterial skin ulcers in Uganda. Lancet 2 (1961) 951-954
5. Dodge O.G., and Lunn H.F. Buruli ulcer: a mycobacterial skin ulcer in a Ugandan child. J Trop Med Hyg 65 (1962) 139-142
6. Aujoulat I., Huguet-Ribas M.P., and Koita Y. Buruli ulcer: an ignored public health problem [in French]. Dev Santé 125 (1996) 22-30
7. World Health Organization. Buruli ulcer. In: Asiedu K., Scherpbier R., and Raviglione M. (Eds). Mycobacterium ulcerans infection (2000), World Health Organization, Geneva
8. World Health Organization. Buruli ulcer disease. Mycobacterium ulcerans infection: an overview of reported cases globally. Wkly Epidemiol Rec 79 (2004) 193-200
9. Debacker M., Aguiar J., Steunou C., et al. Mycobacterium ulcerans disease (Buruli ulcer) in a Rural Hospital, Southern Benin, 1997-2001. Emerg Infect Dis 10 (2004) 1391-1398
10. Johnson R.C., Makoutodé M., Sopoh G.E., et al. Buruli ulcer in Benin. Emerg Infect Dis 11 (2005) 500-501
11. Stragier P., Ablordey A., Bayonne L.M., et al. First report on heterogeneity among Mycobacterium ulcerans from different African countries. Emerg Infect Dis 12 (2006) 844-847
12. Oluwasanmi J.O., Solanke T.F., Olurin E.O., Itayemi S.O., Alabi G.O., and Lucas A.O. Mycobacterium ulcerans (Buruli) skin ulceration in Nigeria. Am J Trop Med Hyg 25 (1976) 122-128
13. Perraudin M.L., Herrault A., and Desbois J.C. Mycobacterium ulcerans infection: clinical and bacteriological study of the first cases recognized in South East Asia. Br J Dermatol 78 (1966) 187-197
14. Monson M.H., Gibson D.W., Connor D.H., Kappes R., and Hienz H.A. Mycobacterium ulcerans in Liberia: a clinicopathologic study of 6 patients with Buruli ulcer. Acta Trop 41 (1984) 165-172
15. Veitch M.G.K., Johnson P.D.R., Flood P.E., Leslie D.E., Street A.C., and Hayman J.A. A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island. Epidemiol Infect 119 (1997) 313-318
16. Portaels F., Elsen P., Guimaraes-Peres A., Fonteyne P.A., and Meyers W.M. Insects in the transmission of Mycobacterium ulcerans infection (Buruli ulcer). Lancet 353 (1999) 986
17. Marsollier L., Robert R., Aubry J., et al. Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol 68 (2002) 4623-4628
18. Debacker M., Aguiar J., Steunou B.S.C., et al. Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health 9 (2004) 1297-1304
19. Debacker M., Portaels F., Aguiar J., et al. Risk factors for Buruli ulcer, Benin. Emerg Infect Dis 12 (2006) 1325-1331
20. Meyers W.M., Shelly W.M., Connor D.H., and Meyers E.K. Mycobacterium ulcerans infections developing at sites of trauma to skin. Am J Trop Med Hyg 23 (1974) 919-923
21. Debacker M., Zinsou C., Aguiar J., Meyers W.M., and Portaels F. First case of Mycobacterium ulcerans disease (Buruli Ulcer) that followed a human bite. Clin Infect Dis 36 (2003) e67-e68
22. Portaels F., Chemlal K., Elsen P., et al. Mycobacterium ulcerans in wild animals. Rev Sci Tech OIE 20 (2001) 252-264
23. Marsollier L., Sévérin T., Aubry J., et al. Aquatic snails, passive hosts of Mycobacterium ulcerans. Appl Environ Microbiol 70 (2004) 6296-6298
24. Eddyani M., Ofori-Adjei D., Teugels G., et al. Potential role for fish in transmission of Mycobacterium ulcerans disease (Buruli ulcer): an environmental study. Appl Environ Microbiol 70 (2004) 5679-5681
25. Portaels F., and Meyers W.M. Buruli ulcer. In: Faber W.R., Hay R.J., and Naafs B. (Eds). Imported skin diseases (2006), Elsevier Gezondheidszorg, Maarssen, The Netherlands 117-129
26. Portaels F., Meyers W.M., Ablordey A., Castro A., Chemlal K., De Rijk P., et al. First cultivation and characterization of Mycobacterium ulcerans from the environment. PloS Negl Trop Dis 2 (2008) e178
27. Marsollier L., Deniaux E., Brodin P., et al. Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. PloS Med 4 (2007) e64
28. Silva M.T., Portaels F., and Pedrosa J. Aquatic insects and Mycobacterium ulcerans: an association relevant to Buruli ulcer control?. PloS Med 4 (2007) e63
29. Tonjum T., Welty D.B., Jantzen E., and Small P.L. Differentiation of Mycobacterium ulcerans, M. marinum, and M. haemophilum: mapping of their relationships to M. tuberculosis by fatty acid profile analysis, DNA-DNA hybridization, and 16S rRNA gene sequence analysis. J Clin Microbiol 36 (1998) 918-925
30. Stinear T.P., Jenkin G.A., Johnson P.D., and Davies J.K. Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J Bacteriol 182 (2000) 6322-6330
31. Mor N., Lutsky I., and Levy L. Response in the hindfoot pad and popliteal lymph node of C57BL mice to infection with Mycobacterium marinum. Isr J Med Sci 17 (1981) 236-244
32. George K.M., Chatterjee D., Gunawardana G., et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283 (1999) 854-857
33. George K.M., Pascopella L., Welty D.M., and Small P.L. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 68 (2000) 877-883
34. Adusumilli S., Mve-Obiang A., Sparer T., Meyers W.M., Hayman J., and Small P.L. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 7 (2005) 1295-1304
35. Oliveira M.S., Fraga A.G., Torrado E., et al. Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun 73 (2005) 6299-6310
36. Walsh D.S., Meyers W.M., Portaels F., et al. High rates of apoptosis in human Mycobacterium ulcerans culture-positive Buruli ulcer skin lesions. Am J Trop Med Hyg 73 (2005) 410-415
37. Gooding T.M., Johnson P.D., Campbell D.E., et al. Immune response to infection with Mycobacterium ulcerans. Infect Immun 69 (2001) 1704-1707
38. Gooding T.M., Johnson P.D., Smith M., Kemp A.S., and Robins-Browne R.M. Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun 70 (2002) 5562-5567
39. Gooding T.M., Kemp A.S., Robins-Browne R.M., Smith M., and Johnson P.D. Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin Infect Dis 36 (2003) 1076-1077
40. Prevot G., Bourreau E., Pascalis H., et al. Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun 72 (2004) 958-965
41. Westenbrink B.D., Stienstra Y., Huitema M.G., et al. Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol 12 (2005) 125-129
42. Stienstra Y., Van Der Graaf W.T., te Meerman G.J., The T.H., de Leij L.F., and van der Werf T.S. Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors. Trop Med Int Health 6 (2001) 554-562
43. Kiszewski A.E., Becerril E., Aguilar L.D., et al. The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol 143 (2006) 445-451
44. Hayman J. Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection. J Clin Pathol 46 (1993) 5-9
45. Hayman J., and McQueen A. The pathology of Mycobacterium ulcerans infection. Pathology 17 (1985) 594-600
46. Van der Werf T.S., Van der Graaf W.T., Tappero J.W., and Asiedu K. Mycobacterium ulcerans infection. Lancet 354 (1999) 1013-1018
47. Stanford J.L., Revill W.D., Gunthorpe W.J., and Grange J.M. The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection. J Hyg 74 (1975) 7-16
48. Dobos K.M., Spotts E.A., Marston B.J., Horsburgh Jr. C.R., and King C.H. Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease. Emerg Infect Dis 6 (2000) 158-164
49. Marston B.J., Diallo M.O., Horsburgh Jr. C.R., et al. Emergence of Buruli ulcer disease in the Daloa region of Cote d'Ivoire. Am J Trop Med Hyg 52 (1995) 219-224
50. Lagarrigue V., Portaels F., Meyers W.M., and Aguiar J. Buruli ulcer: risk of bone involvement! A propos of 33 cases observed in Benin. Med Trop 60 (2000) 262-266
51. Noeske J., Kuaban C., Rondini S., et al. Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg 70 (2004) 520-526
52. Portaels F., Aguiar J., Debacker M., et al. BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli Ulcer disease. Infect Immun 72 (2004) 62-65
53. Tanghe A., Content J., Van Vooren J.P., Portaels F., and Huygen K. Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun 69 (2001) 5403-5411
54. Coutanceau E., Legras P., Marsollier L., Reysset G., Cole S.T., and Demangel C. Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer. Microbes Infect 8 (2006) 2075-2081
55. Phillips R., Horsfield C., Kuijper S., et al. Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis. Clin Vaccine Immunol 13 (2006) 253-257
56. Phillips R., Horsfield C., Mangan J., et al. Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response. Infect Immun 74 (2006) 2917-2924
57. Fenner F. The pathogenic behavior of Mycobacterium ulcerans and Mycobacterium balnei in the mouse and the developing chick embryo. Am Rev Tuberc 73 (1956) 650-673
58. Krieg R.E., Hockmeyer W.T., and Connor D.H. Toxin of Mycobacterium ulcerans. Production and effects in guinea pig skin. Arch Dermatol 110 (1974) 783-788
59. Read J.K., Heggie C.M., Meyers W.M., and Connor D.H. Cytotoxic activity of Mycobacterium ulcerans. Infect Immun 9 (1974) 1114-1122
60. van der Werf T.S., Stienstra Y., Johnson R., et al. Mycobacterium ulcerans disease (Buruli ulcer): a review. Bull WHO 83 (2005) 785-791
61. Johnson PDR, Stinear TP, Small PLC, et al. Buruli-ulcer - new insights into a neglected disease. PLoS Medicine 2005;26:e108:0283-6.
62. Torrado E., Fraga A.G., Castro A.G., et al. Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 75 (2007) 977-987
63. Coutanceau E., Marsollier L., Brosch R., et al. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 7 (2005) 1187-1196
64. Mehta P.K., King C.H., White E.H., Murtagh Jr. J.J., and Quinn F.D. Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication. Infect Immun 64 (1996) 2673-2679
65. Ramakrishnan L., and Falkow S. Mycobacterium marinum persists in cultured mammalian cells in a temperature-restricted fashion. Infect Immun 62 (1994) 3222-3229
66. Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 47 (2003) 833-836
67. Kaufmann S.H., Cole S.T., Mizrahi V., Rubin E., and Nathan C. Mycobacterium tuberculosis and the host response. J Exp Med 201 (2005) 1693-1697
68. Turner O.C., Keefe R.G., Sugawara I., Yamada H., and Orme I.M. SWR mice are highly susceptible to pulmonary infection with Mycobacterium tuberculosis. Infect Immun 71 (2003) 5266-5272
69. Dobos K.M., Quinn F.D., Ashford D.A., Horsburgh C.R., and King C.H. Emergence of a unique group of necrotizing mycobacterial diseases. Emerg Infect Dis 5 (1999) 367-378
70. Gao L.Y., Guo S., McLaughlin B., Morisaki H., Engel J.N., and Brown E.J. A mycobacterial virulence gene cluster extending RD1 is required for cytolysis, bacterial spreading and ESAT-6 secretion. Mol Microbiol 53 (2004) 1677-1693
71. Silva M.T., Silva M.N., and Appelberg R. Neutrophil-macrophage cooperation in the host defence against mycobacterial infections. Microb Pathog 6 (1989) 369-380
72. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 61 (1997) 375-380
73. Gregory S.H., and Wing E.J. Neutrophil-Kupffer cell interaction: a critical component of host defenses to systemic bacterial infections. J Leukoc Biol 72 (2002) 239-248
74. Richter-Dahlfors A., Buchan A.M., and Finlay B.B. Murine salmonellosis studied by confocal microscopy: Salmonella typhimurium resides intracellularly inside macrophages and exerts a cytotoxic effect on phagocytes in vivo. J Exp Med 186 (1997) 569-580
75. Rondini S., Horsfield C., Mensah-Quainoo E., Junghanss T., Lucas S., and Pluschke G. Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA. J Pathol 208 (2006) 119-128
76. Knodler L.A., and Finlay B.B. Salmonella and apoptosis: to live or let die?. Microbes Infect 3 (2001) 1321-1326
77. Alli O.A., Gao L.Y., Pedersen L.L., et al. Temporal pore formation-mediated egress from macrophages and alveolar epithelial cells by Legionella pneumophila. Infect Immun 68 (2000) 6431-6440
78. Huygen K. Prospects for vaccine development against Buruli disease. Expert Rev Vaccines 2 (2003) 561-569
79. Connor D.H., Meyers W.M., and Krieg R.E. Infection by Mycobacterium ulcerans. In: Connor D.H., and Binford C.H. (Eds). Pathology of Tropical and extraordinary diseases. An atlas Vol 1 (1976), Armed Forces Institute of Pathology, Washington, DC 26-235
80. Guarner J., Bartlett J., Whitney E.A., et al. Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis 9 (2003) 651-656
81. Dodge O.G. Mycobacerial skin ulcers in Uganda: histopathological and experimental aspects. J Pathol Bacteriol 88 (1964) 167-174
82. Meyers W.M. Mycobacterial infections of the skin (including leprosy, tuberculosis of the skin, Buruli ulcer, and less common mycobacterial infections). In: Doerr W., and Seifert G. (Eds). Tropical pathology. 2nd ed. (1995), Springer-Verlag, Berlin 291-377
83. Portaels F. Epidemiology of mycobacterial diseases. Clin Dermatol 13 (1995) 207-222
84. Prasad R. Pulmonary sarcoidosis and chronic cutaneous atypical mycobacter ulcer. Aust Fam Physician 22 (1993) 755-758
85. Revill W.D.L., Morrow R.H., Pike M.C., and Ateng J. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet (1973) 873-877
86. Portaels F., Zinsou C., Aguiar J., et al. Les atteintes osseuses dans l'ulcère de Buruli: a propos de 73 cas. Bull Séances Acad R Sci Outre-Mer 49 (2003) 161-190
87. Pszolla N., Sarkar M.R., Strecker W., et al. Buruli ulcer-a systemic disease. Clin Infect Dis 37 (2003) e78-e82
88. In: Portaels F., Johnson P., and Meyers W.M. (Eds). Buruli ulcer: diagnosis of Mycobacterium ulcerans disease (2001), World Health Organization, Geneva
89. Yip M., Porter J.L., Fyfe J., et al. Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor. J Bacteriol 189 (2007) 2021-2029
90. Stragier P., Ablordey A., Durnez L., and Portaels F. VNTR analysis differentiates Mycobacterium ulcerans and IS2404 positive mycobacteria. Syst & Appl Microbiol 30 (2007) 525-530
91. World Health Organization. Provisional guidance on the role specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer) (2004), World Health Organization, Geneva
92. In: Buntine J., and Crofts K. (Eds). Buruli ulcer: management of Mycobacterium ulcerans disease (2001), World Health Organization, Geneva
93. Debacker M., Aguiar J., Steunou C., Zinsou C., Meyers W.M., and Portaels F. Buruli ulcer recurrence, Benin. Emerg Infect Dis 11 (2005) 584-589
94. Wansbrough-Jones M., and Phillips R. Buruli ulcer: emerging from obscurity. Lancet 367 (2006) 1849-1858
95. Guédénon A., Zinsou C., Josse R., et al. Traditional treatment of Buruli ulcer in Bénin. Arch Dermatol 131 (1995) 741-742
96. Chauty A., Ardant M.F., Adeye A., Euverte H., Guédénon A., Johnson C., et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51 (2007) 4029-4035